149 related articles for article (PubMed ID: 29289982)
21. Survival and risk factors for mortality in pediatric patients with acute myeloid leukemia in a single reference center in low-middle-income country.
Lins MM; Mello MJG; Ribeiro RC; De Camargo B; de Fátima Pessoa Militão de Albuquerque M; Thuler LCS
Ann Hematol; 2019 Jun; 98(6):1403-1411. PubMed ID: 30915498
[TBL] [Abstract][Full Text] [Related]
22. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia.
Candoni A; Damiani D; Michelutti A; Masolini P; Michieli M; Michelutti T; Geromin A; Fanin R
Eur J Haematol; 2003 Jul; 71(1):1-8. PubMed ID: 12801292
[TBL] [Abstract][Full Text] [Related]
23. [Therapy of acute promyelocytic leukemia in Czechia: results and analysis of prognostic factors].
Schwarz J; Korístek Z; Starý J; Zák P; Kozák T; Marková J; Michalová K; Dvoráková D; Mayer J; Cetkovský P
Vnitr Lek; 2008; 54(7-8):757-70. PubMed ID: 18780575
[TBL] [Abstract][Full Text] [Related]
24. An effective early death scoring system for predicting early death risk in
Cai P; Wu Q; Wang Y; Yang X; Zhang X; Chen S
Leuk Lymphoma; 2020 Aug; 61(8):1989-1995. PubMed ID: 32228267
[TBL] [Abstract][Full Text] [Related]
25. Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens.
Hecht A; Doll S; Altmann H; Nowak D; Lengfelder E; Röllig C; Ehninger G; Spiekermann K; Hiddemann W; Weiß C; Hofmann WK; Nolte F; Platzbecker U
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):889-896.e5. PubMed ID: 28923666
[TBL] [Abstract][Full Text] [Related]
26. Influence of cytokines on early death and coagulopathy in newly diagnosed patients with acute promyelocytic leukemia.
Zhao S; Ge Y; Li Z; Yang T
Front Immunol; 2023; 14():1100151. PubMed ID: 37063881
[TBL] [Abstract][Full Text] [Related]
27. Autologous transplant remains the preferred therapy for relapsed APL in CR2.
Ganzel C; Mathews V; Alimoghaddam K; Ghavamzadeh A; Kuk D; Devlin S; Wang H; Zhang MJ; Weisdorf D; Douer D; Rowe JM; Polge E; Esteve J; Nagler A; Mohty M; Tallman MS
Bone Marrow Transplant; 2016 Sep; 51(9):1180-3. PubMed ID: 27088379
[TBL] [Abstract][Full Text] [Related]
28. Long-term survey of outcome in acute promyelocytic leukemia: a single center experience in 340 patients.
Liu YJ; Wu DP; Liang JY; Qiu HY; Jin ZM; Tang XW; Fu CC; Ma X
Med Oncol; 2011 Dec; 28 Suppl 1():S513-21. PubMed ID: 21069477
[TBL] [Abstract][Full Text] [Related]
29. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
[TBL] [Abstract][Full Text] [Related]
30. Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy.
Lou Y; Suo S; Tong Y; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Jin J
Ann Hematol; 2014 Jun; 93(6):941-8. PubMed ID: 24408159
[TBL] [Abstract][Full Text] [Related]
31. [Clinical features and prognostic analysis of high-risk acute promyelocytic leukemia patients].
Pei RZ; Si T; Lu Y; Zhang PS; Liu XH; Ye PP; Chen D; Du XH; Ma JX; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2016 May; 37(5):360-5. PubMed ID: 27210868
[TBL] [Abstract][Full Text] [Related]
32. Effectivity of a modified Sanz risk model for early death prediction in patients with newly diagnosed acute promyelocytic leukemia.
Lou Y; Ma Y; Sun J; Suo S; Tong H; Qian W; Mai W; Meng H; Jin J
Ann Hematol; 2017 Nov; 96(11):1793-1800. PubMed ID: 28823055
[TBL] [Abstract][Full Text] [Related]
33. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
[TBL] [Abstract][Full Text] [Related]
34. Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.
Braun T; Cereja S; Chevret S; Raffoux E; Beaumont M; Detourmignies L; Pigneux A; Thomas X; Bordessoule D; Guerci A; Lamy T; Recher C; Poiré X; Tournilhac O; Spertini O; Chomienne C; Degos L; Dombret H; Adès L; Fenaux P;
Cancer; 2015 Jul; 121(14):2393-9. PubMed ID: 25845577
[TBL] [Abstract][Full Text] [Related]
35. Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL).
Park S; Lee SJ; Kim K; Jang JH; Kim DH; Lee KH; Lee JH; Lee JH; Kim DY; Jang DY; Kim H; Park JH; Ryoo HM; Bae SH; Kim MK; Hyun MS; Joo YD; Lee WS; Lee SM; Jung CW
Int J Hematol; 2013 Mar; 97(3):388-96. PubMed ID: 23397209
[TBL] [Abstract][Full Text] [Related]
36. Effect of initial absolute monocyte count on survival outcome of patients with de novo non-M3 acute myeloid leukemia.
Feng J; Zhang W; Wu J; Gao S; Ye H; Sun L; Chen Y; Yu K; Xing CY
Leuk Lymphoma; 2016 Nov; 57(11):2548-54. PubMed ID: 27074049
[TBL] [Abstract][Full Text] [Related]
37. Economic evaluation of arsenic trioxide compared to all-trans retinoic acid + conventional chemotherapy for treatment of relapsed acute promyelocytic leukemia in Canada.
Lachaine J; Mathurin K; Barakat S; Couban S
Eur J Haematol; 2015 Sep; 95(3):218-29. PubMed ID: 25354894
[TBL] [Abstract][Full Text] [Related]
38. Treatment of acute promyelocytic leukemia with PETHEMA LPA 99 protocol: a Tunisian single center experience.
Jeddi R; Ghédira H; Menif S; Ben Neji H; Ben Amor R; Kacem K; Aissaoui L; Bouteraâ W; Abdennebi Y; Raihane BL; Gouider E; Raouf H; Hèla BA; Saad A; Zaher B; Meddeb B
Hematology; 2010 Aug; 15(4):204-9. PubMed ID: 20670478
[TBL] [Abstract][Full Text] [Related]
39. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
40. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
